قالب وردپرس درنا توس
Home / Health / Kentucky begins testing potential COVID-19 vaccine

Kentucky begins testing potential COVID-19 vaccine



Kentucky will soon begin testing a potential COVID-19 vaccine. On Thursday, the University of Kentucky along with several regional hospitals, including one in Louisville, were selected as testing sites for Johnson and Johnson’s Janssen Pharmaceutical Company. Clinical research phase 3 research. Phase 3 was designed to evaluate the safety and efficacy of a single dose of vaccine versus placebo in a test group of about 60,000 people. About half of those participants will be from the United States and about 2,000 from the Commonwealth. “I am honored to lead this trial to fight. This is an opportunity for all Kentuckians, all Americans to do the right thing to eliminate this evils.”

; Dr. Richard Greenberg, University of Kentucky, said in a press conference: With four decades of vaccine development experience, including successes with disease and smallpox, Greenberg has been chosen to take the lead. in local efforts. The UK will partner with Baptist Health Lexington and Norton Healthcare in Louisville. “We need to unite in this once-in-a-lifetime challenge to overcome the coronavirus pandemic. As a state, we have joined the trial of this vaccine with the common goal to end the pandemic,” Dr. David Dougherty, an infectious disease specialist at Baptist Health Lexington, said. Greenberg also looks forward to cooperation and possible success, in the fifth section saying, “This seems to be an extremely good vaccine.” Others in the group emphasized safety would be important. leading in a two-year trial period. Dr Paul Schulz, epidemiologist atorton Healthcare explains, “Stage 3 shows that the product has been tested, it may be safe to extend testing to a large number of the population.You may have enough data to determine if the drug actually works. “The researchers said they were looking for those most affected, the older and minority populations and at risk of the disease – those in front line. “We can’t bring the product to market, so we can say, if we don’t have people willing to apply for these studies, it’s not possible,” Schulz said. were asked about the importance of engaging with participants. Greenberg says this is an opportunity to change all of that quickly, stressing healthcare workers and even everyday families. “I’ll tell you one thing: the virus isn’t exhausted yet. The virus is out there and it will be out there and it will continue to be out there, so we really need to look at what they are.” I can do it to stop it, “he said. Want to join? Subscribe to research does not necessarily mean that you will be selected. Participants will be compensated over a two-year period. During the first year, they will be monitored twice a week using one application. For the second year, they will be monitored only twice a month. For more information about the study and how to participate, click here. If you have any questions, contact the team at stopcovidky@uky.edu

Kentucky will soon begin testing the potential COVID-19 vaccine.

On Thursday, it was announced that the University of Kentucky, along with several hospitals in the region, including one in Louisville, were selected as the testing site for the Pharmaceutical Company’s Phase 3 clinical study. Janssen products by Johnson and Johnson.

Phase 3 was designed to evaluate the safety and efficacy of a single dose of vaccine versus a placebo in a test group of about 60,000 people. About half of the participants will be from the United States and about 2,000 from the Commonwealth.

Dr Richard Greenberg, of the University of Kentucky, said: “I am honored to lead this trial to fight. This is an opportunity for all Kentuckians, all Americans to do the right thing to eliminate bad. this incident, “said Dr. Richard Greenberg, University of Kentucky.

With four decades of experience in vaccine development, including successes with disease and smallpox, Greenberg has been selected to be at the forefront of local efforts. The UK will partner with Baptist Health Lexington and Norton Healthcare in Louisville.

“We need to unite in this once-in-a-lifetime challenge to overcome the coronavirus pandemic. As a state, we have come together to test this vaccine with the common goal of ending the pandemic. “, Said Dr. David Dougherty, an infectious disease specialist at Baptist Health Lexington, said.

Greenberg is also looking forward to cooperation and possible success, saying in Part Five: “This looks like an extremely good vaccine.”

Others in the group emphasized safety will be of primary importance during the two years of the trial.

Dr Paul Schulz, an epidemiologist at Norton Healthcare explains, “Stage 3 shows that the product has passed a testing process, which may be safe when extending testing to a large number of the population where you might be enough data to determine if the drug actually works. “

The researchers said they were looking for those most affected, the older and minority populations, and at risk – those at the front.

“We can’t bring the product to market, so we can say, if we don’t have people willing to apply for these studies, it’s not possible,” Schulz said. were asked about the importance of engaging with participants.

While Kentucky continues to see a rapid increase in the number of cases, stressing healthcare workers and even families every day, Greenberg sees it as an opportunity to change everything. both.

“I’ll tell you one thing: the virus isn’t exhausted yet. The virus is out there and it will be there and it will continue there, so we really need to look at what we have. You can do it to stop it, “he said.

You want to join?

Being enrolled in the study does not necessarily mean you will be selected. Participants will be compensated over a two-year period.

During the first year, they will be monitored twice a week using one application. For the second year, they will be monitored only twice a month.

For more information on the study, and to know how to participate, click here.

If you have any questions, contact the team at stopcovidky@uky.edu


Source link